CSTL PEER ANALYSIS

Castle Biosciences Inc — metric-by-metric comparison with peers and the industry median

CSTLCastle Biosciences Inc

🇺🇸 USA · NASDAQ · Healthcare · Diagnostics & Research

Value it Duel

Overall Profile & Returns

· Diagnostics & Research

Position Within Industry

0 = weak quartile, 100 = strong quartile

CSTLIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	CSTL	GENIL	RYM	SNZ	GSK	ECILC	Ind. Median
P/E	—	46.41	—	5.89●	13.84	—	28.95
P/B	1.53	3.44	0.32●	0.46	4.52	0.79	3.39
EV/EBITDA	—	13.96	—	20.30	8.32●	33.51	20.39
P/S	2.08	1.84	1.11●	4.24	2.46	4.98	4.21

Financial Health
Metric	CSTL	GENIL	RYM	SNZ	GSK	ECILC	Ind. Median
Current Ratio	6.75●	1.33	0.55	0.34	0.79	1.73	1.87
Debt/Equity	8.0%	41.0%	39.0%	59.6%	106.7%	5.9%●	49.3%
NetDebt/EBITDA	310.00	1.10	-6.24●	11.44	1.35	-0.10	1.92

Profitability
Metric	CSTL	GENIL	RYM	SNZ	GSK	ECILC	Ind. Median
Net Margin	-3.8%	4.0%	-60.1%	72.0%●	17.8%	-3.6%	6.7%
ROE	-2.8%	8.7%	-16.8%	8.2%	36.4%●	-0.6%	6.4%
ROA	-2.4%	4.8%	-5.8%	3.0%	9.4%●	-0.5%	3.3%
EBITDA Margin	-0.2%	14.3%	-21.8%	47.9%●	35.3%	14.8%	18.8%

Growth + Dividend
Metric	CSTL	GENIL	RYM	SNZ	GSK	ECILC	Ind. Median
Rev. Growth	-2.1%	16.3%	215.1%●	13.3%	4.0%	-2.3%	9.1%
NI Growth	—	146.6%●	—	-23.6%	84.9%	—	12.4%
Div. Yield	—	0.0%	—	3.4%●	3.3%	2.6%	0.8%
Payout	—	0.0%	—	12.5%	44.5%	-365.1%	23.2%

Valuation
Metric	CSTL	FLGT	MYGN	OPK	NEO	CDNA	Ind. Median
P/E	—	—	—	—	—	—	28.95
P/B	1.53	0.61	1.63	0.89	0.44●	4.67	3.39
EV/EBITDA	—	—	—	—	—	121.63	20.39
P/S	2.08	1.99	0.66	1.84	0.49●	3.55	4.21

Financial Health
Metric	CSTL	FLGT	MYGN	OPK	NEO	CDNA	Ind. Median
Current Ratio	6.75●	5.31	2.40	3.61	4.42	3.40	1.87
Debt/Equity	8.0%	1.0%●	62.7%	33.0%	49.3%	7.8%	49.3%
NetDebt/EBITDA	310.00	4.55	-0.26	-1.59	-7.82	-15.21●	1.92

Profitability
Metric	CSTL	FLGT	MYGN	OPK	NEO	CDNA	Ind. Median
Net Margin	-3.8%	-23.0%	-48.2%	-36.6%	-13.3%	-2.0%●	6.7%
ROE	-2.8%	-6.8%	-76.7%	-16.9%	-11.6%	-2.4%●	6.4%
ROA	-2.4%	-6.2%	-47.6%	-10.7%	-6.7%	-1.8%●	3.3%
EBITDA Margin	-0.2%	-18.3%	-40.3%	-6.0%	-4.5%	2.6%●	18.8%

Growth + Dividend
Metric	CSTL	FLGT	MYGN	OPK	NEO	CDNA	Ind. Median
Rev. Growth	-2.1%	9.5%	-0.3%	-15.7%	10.9%	19.2%●	9.1%
NI Growth	—	—	—	—	—	—	12.4%
Div. Yield	—	—	—	—	—	—	0.8%
Payout	—	—	—	—	—	—	23.2%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on CSTL

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 8, 26. This content is for informational purposes only and is not investment advice.